RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

Stock Information for RenovoRx Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RenovoRx Inc.

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP(TM) Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP(TM) Therapy Platform Presented at 2026 SIR Annual Scientific Meeting
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.